{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:11:50Z","timestamp":1761217910848,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":3459,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer Supplements"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/s1359-6349(03)00104-6","type":"journal-article","created":{"date-parts":[[2004,1,23]],"date-time":"2004-01-23T05:18:16Z","timestamp":1074835096000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy?"],"prefix":"10.1016","volume":"2","author":[{"given":"M","family":"Aapro","sequence":"first","affiliation":[]},{"given":"E","family":"Bajetta","sequence":"additional","affiliation":[]},{"given":"M","family":"Freund","sequence":"additional","affiliation":[]},{"given":"T.J","family":"Littlewood","sequence":"additional","affiliation":[]},{"given":"J.W.R","family":"Nortier","sequence":"additional","affiliation":[]},{"given":"B","family":"Rapoport","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1359-6349(03)00104-6_BIB1","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","article-title":"Survival determinants in extensive-stage non-small-cell lung cancer","volume":"9","author":"Albain","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0360-3016(01)01488-2","article-title":"Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx","volume":"50","author":"Glaser","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"Suppl. 4","key":"10.1016\/S1359-6349(03)00104-6_BIB3","first-page":"13","article-title":"Relevance of oxygen in radiation oncology","volume":"174","author":"Molls","year":"1998","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB4","first-page":"126","article-title":"Prognostic factors for survival in inoperable non-small-cell lung cancer","volume":"20","author":"Ohlhauser","year":"1997","journal-title":"Onkologie"},{"key":"10.1016\/S1359-6349(03)00104-6_BIB5","first-page":"4509","article-title":"Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix","volume":"56","author":"H\u00f6ckel","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/028418698430278","article-title":"Tumor hypoxia and gene expression\u2014implications for malignant progression and therapy","volume":"37","author":"Sutherland","year":"1998","journal-title":"Acta Oncol."},{"issue":"Suppl. 8","key":"10.1016\/S1359-6349(03)00104-6_BIB7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0093-7754(01)90210-6","article-title":"Oxygen status of malignant tumors","volume":"28","author":"Vaupel","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB9","first-page":"3339","article-title":"Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma","volume":"50","author":"Teicher","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB10","series-title":"Blood Perfusion and Microenvironment of Human Tumors. Implications for Clinical Radiooncology","first-page":"101","article-title":"Significance of hemoglobin concentrations for treatment outcome","author":"Grau","year":"1998"},{"key":"10.1016\/S1359-6349(03)00104-6_BIB11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/oxfordjournals.annonc.a058423","article-title":"Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors","volume":"4","author":"Ludwig","year":"1993","journal-title":"Ann. Oncol."},{"issue":"Suppl. 6","key":"10.1016\/S1359-6349(03)00104-6_BIB12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(00)90062-3","article-title":"Management of cancer-related anemia","volume":"37","author":"Soignet","year":"2000","journal-title":"Semin. Hematol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice","volume":"15","author":"Glaspy","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB14","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study","volume":"16","author":"Demetri","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB15","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/S1359-6349(03)00104-6_BIB18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1998","journal-title":"Biometrika"},{"issue":"series B","key":"10.1016\/S1359-6349(03)00104-6_BIB19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables [with discussion]","volume":"34","author":"Cox","year":"1972","journal-title":"J. Royal Statist. Soc."},{"issue":"Suppl. 1","key":"10.1016\/S1359-6349(03)00104-6_BIB20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000204780","article-title":"Recombinant human erythropoietin in the treatment of the anemia of cancer","volume":"87","author":"Abels","year":"1992","journal-title":"Acta Haematol."},{"issue":"Suppl. 3","key":"10.1016\/S1359-6349(03)00104-6_BIB21","first-page":"21","article-title":"Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia","volume":"21","author":"Henry","year":"1994","journal-title":"Semin. Oncol."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB22","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5","article-title":"Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin","volume":"73","author":"Leitgeb","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/S1359-6349(03)00104-6_BIB23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S1359-6349(03)00104-6_BIB24","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E","article-title":"The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix","volume":"86","author":"Grogan","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/S1359-6349(03)00104-6_BIB25","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"}],"container-title":["European Journal of Cancer Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359634903001046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359634903001046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:04:36Z","timestamp":1761217476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359634903001046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S1359634903001046"],"URL":"https:\/\/doi.org\/10.1016\/s1359-6349(03)00104-6","relation":{},"ISSN":["1359-6349"],"issn-type":[{"type":"print","value":"1359-6349"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1359-6349(03)00104-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}